Biogen Inc.

Contributing Author

Recent Articles by Biogen Inc.

Dec-08	"LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List BIIB GlobeNewswire
Dec-05	Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting BIIB GlobeNewswire
Dec-03	Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 BIIB GlobeNewswire
Dec-02	New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF BIIB GlobeNewswire
Dec-01	Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting BIIB GlobeNewswire
Nov-27	Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI" for the Treatment of Early Alzheimer's Disease in Japan BIIB GlobeNewswire
Nov-24	Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions BIIB GlobeNewswire
Nov-20	Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference BIIB GlobeNewswire
Nov-17	Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments BIIB GlobeNewswire
Nov-17	High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy BIIB GlobeNewswire
Nov-14	Biogen Completes Acquisition of Alcyone Therapeutics BIIB GlobeNewswire
Nov-13	"LEQEMBI" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom BIIB GlobeNewswire
Nov-03	Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025 BIIB GlobeNewswire
Oct-26	Health Canada Grants Authorization for "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease BIIB GlobeNewswire
Oct-24	Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio BIIB GlobeNewswire
Oct-22	Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 BIIB GlobeNewswire
Oct-13	LEQEMBI IQLIK(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" BIIB GlobeNewswire
Oct-09	Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome BIIB GlobeNewswire
Oct-06	Eisai and Biogen Announce U.S. Availability of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease BIIB GlobeNewswire
Sep-28	"LEQEMBI" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China BIIB GlobeNewswire
Sep-24	LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia BIIB GlobeNewswire
Sep-23	Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen BIIB GlobeNewswire
Sep-18	Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates BIIB GlobeNewswire
Sep-17	Biogen Receives European Commission Approval for ZURZUVAE (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe BIIB GlobeNewswire
Sep-02	Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status BIIB GlobeNewswire
Sep-02	Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome BIIB GlobeNewswire
Aug-29	FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease BIIB GlobeNewswire
Aug-25	Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress BIIB GlobeNewswire
Aug-25	Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI (lecanemab) BIIB GlobeNewswire
Aug-11	Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome BIIB GlobeNewswire
Jul-30	Two-Year Real-World Study of LEQEMBI in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 BIIB GlobeNewswire
Jul-25	ZURZUVAE (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression BIIB GlobeNewswire
Jul-21	Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025 BIIB GlobeNewswire
Jul-21	Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary BIIB GlobeNewswire
Jul-10	Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress BIIB GlobeNewswire
Jun-30	Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy BIIB GlobeNewswire
Jun-27	New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA BIIB GlobeNewswire
Jun-25	Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results BIIB GlobeNewswire
Jun-18	Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia BIIB GlobeNewswire
Jun-12	Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity BIIB GlobeNewswire
May-27	Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies BIIB GlobeNewswire

Biogen Inc.

Recent Articles by Biogen Inc.

Upgrade your FINVIZ experience